Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Blood stem cell allografting

A P Haynes1, N H Russell

  • 1Nottingham City Hospital, Department of Haematology, UK.

Current Opinion in Hematology
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Peripheral blood stem cells offer benefits for allogeneic transplantation, with G-CSF mobilization showing effectiveness. Allogeneic stem cells may provide faster engraftment than marrow, though further study is needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bone marrow transplantation·2017
Same author

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Leukemia·2017
Same author

Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.

Bone marrow transplantation·2017
Same author

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

Bone marrow transplantation·2016
Same author

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Blood cancer journal·2016
Same author

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Leukemia·2016
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Transplantation Immunology

Background:

  • Peripheral blood stem cells (PBSCs) are increasingly preferred for autologous rescue.
  • This success suggests potential advantages for allogeneic transplantation.

Purpose of the Study:

  • To evaluate the efficacy and safety of allogeneic PBSC transplantation.
  • To compare PBSC allografts with traditional bone marrow allografts.

Main Methods:

  • Mobilization of stem cells in normal donors using granulocyte-colony stimulating factor (G-CSF).
  • Comparison of cellular composition, engraftment kinetics, and graft-versus-host disease (GVHD) between PBSC and bone marrow allografts.

Main Results:

  • G-CSF effectively mobilizes PBSCs with minimal side effects.

Related Experiment Videos

  • PBSC allografts contain higher numbers of CD34+ progenitors, T lymphocytes, and NK cells.
  • Initial observations suggest more rapid engraftment with PBSCs compared to marrow, pending randomized trials.
  • No significant difference in acute GVHD between PBSC and marrow allografts was observed.

    • Conclusions:

    • Allogeneic stem cell transplantation is a viable and potentially advantageous alternative to bone marrow transplantation.
    • Further long-term follow-up is required to fully assess chronic GVHD and relapse risks.
    • The use of allogeneic stem cells is expected to increase in both matched and mismatched transplant settings.